Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


«12...1718192021222324252627...3940»
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Enrollment open:  SWIFT: Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV (clinicaltrials.gov) -  Jul 7, 2022   
    P=N/A,  N=80, Recruiting, 
    In this post-hoc analysis with modest subgroup numbers, once-weekly semaglutide appeared consistently more efficacious versus comparators across age and BMI subgroups in Japanese patients, with a similar safety profile. Not yet recruiting --> Recruiting
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Journal:  High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management. (Pubmed Central) -  Jun 29, 2022   
    Most importantly, the results were obtained after three months of treatment and persisted thereafter. High-dose once-weekly semaglutide can significantly reduce weight, and although gastrointestinal adverse effects were common, it is generally well tolerated.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Targeting cardiovascular risk factors with GLP-1 RAs in people with obesity (Stockholm) -  Jun 27, 2022 - Abstract #ESC2022ESC_5249;    
    Urgent need remains for larger studies focussing on liver biopsy. Sponsored by Novo Nordisk •To recognize obesity as a chronic disease and establish its relation to CV risk factors •To present the improvements in cardiometabolic risk factors in PwO using GLP-1 RAs from clinical evidence •To explore future perspectives of semaglutide 2.4 mg in CV space Disclaimer: Semaglutide 2.4 mg once weekly is being investigated in subjects to improve CV risk and with heart failure with preserved ejection fraction
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity. (Pubmed Central) -  Jun 25, 2022   
    Sponsored by Novo Nordisk •To recognize obesity as a chronic disease and establish its relation to CV risk factors •To present the improvements in cardiometabolic risk factors in PwO using GLP-1 RAs from clinical evidence •To explore future perspectives of semaglutide 2.4 mg in CV space Disclaimer: Semaglutide 2.4 mg once weekly is being investigated in subjects to improve CV risk and with heart failure with preserved ejection fraction Semaglutide offers adults with obesity or overweight a new treatment in conjunction with a weight management program consisting of reduced calorie diet and increased physical activity.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Enrollment closed:  Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis (clinicaltrials.gov) -  Jun 22, 2022   
    P3,  N=375, Active, not recruiting, 
    At a willingness-to-pay threshold of CAD50,000 per QALY gained, once-weekly semaglutide 1 mg was cost-effective over 40 years versus once-daily canagliflozin 300 mg for the treatment of T2DM in patients failing to maintain glycemic control with metformin alone. Recruiting --> Active, not recruiting
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Review, Journal:  The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. (Pubmed Central) -  Jun 19, 2022   
    For the first time, there may be a suggestion that these behavioral programs might not increase weight reduction beyond the effect of semaglutide. Nevertheless, the importance of nutritional support during substantial weight loss with pharmacotherapy needs to be re-evaluated.
  • ||||||||||  FDA event, Journal:  Comparison table: Some FDA-approved drugs for weight management. (Pubmed Central) -  Jun 11, 2022   
    Event ascertainment is ongoing, and the FLOW trial will provide evidence for the potential of semaglutide to improve kidney and CV outcomes in the T2D population. No abstract available
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonists. (Pubmed Central) -  Jun 9, 2022   
    In a 21-day study in DIO mice, once-weekly administration of 3d and 3h significantly induced body weight loss, improved glucose tolerance, and normalized lipid metabolism, to a greater extent than semaglutide. The current study showed the antidiabetic and antiobesity potentials of GLP-1R/CCK-2R dual agonists that warrant further investigation.